In total, 18 companies and two top executives, including Mylan's president, are now named in the complaint. Mylan's …
Other examples include Valeant picking up Isuprel and Nitropress and increasing prices by six-fold and three-fold respectively, and Mylan hiking up EpiPen prices ... depleting its stock as well. The industry is in a perpetual blame …
Abbott Laboratories (NYSE: ABT) has agreed to sell its non-U.S. generic drug business to Mylan Inc. (NASDAQ: MYL) in an all-stock transaction valued at $5.3 billion. Mylan will form a new company based in the Netherlands, of which …
A rating of 3 would signify a consensus Hold recommendation. Investors who are keeping close eye on Mylan N.V. …
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
This quick video takes a look at Mylan (MYL) ahead of its earnings report. The pharma company has been under pressure for much of 2016 while a bottom 33% industry rank isn’t helping matters either. Even more troubling than the weak …
the stock’s 4.4 percent dividend yield, and aggressive share buybacks, GM’s 10 …
Momenta Pharmaceuticals, Inc. (MNTA - Free Report) and Mylan N.V. (MYL - Free Report) have announced that the companies will initiate a patient clinical trial of M710 — a proposed biosimilar of Regeneron Pharmaceuticals’ (REGN - …
(Kacik, 1/18) Modern Healthcare: Generic Drugmaker Stocks Dip Amid Reports Of Competition From Health Systems …
The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects. Generic drugs company Mylan has announced its intention of delisting from the Tel Aviv Stock Exchange. Mylan has been traded in Tel Aviv …